Global Biologics CDMO Market is anticipated to witness a healthy growth of 15% to reach $35 billion by 2025

The growth in biopharmaceutical sales and pipeline and increasing complexity of molecules would drive the outsourcing of biologics development and manufacturing services across the product lifecycle. Moreover, the rising number of molecules (recombinant proteins and antibodies) in the pipeline being developed by small and virtual biotechs (>60%) who lack in-house manufacturing capabilities and expertise to bring their candidates to market would in turn boost the demand for CDMO services.

Huge Potential for Upturn in Outsourcing Ratio

The outsourcing ratio in biologics manufacturing is much less compared to that for small molecules, providing ample opportunity for growth. With the increasingly complex and rapidly evolving biopharma industry, companies are looking for CDMOs who can provide significant regulatory leadership and expertise in all stages from early-stage discovery to commercialization. Moreover, newer technologies like viral vector, mRNA, and cell & gene therapy are where demand exceeds supply, and capabilities may not exist even in large biopharma thereby offering wide scope for outsourcing to CDMOs.

Market Trend Towards Full-service CDMOs/One-stop-shop Model

Large pharma companies prefer to select a CDMO that also has early-stage development capabilities, as switching costs are significantly higher once cell lines and processes are established. Due to the complexities intrinsic to biologics development, biopharma companies look for a full-service CDMO handling all services, from cell line development through fill-finish and packaging.

CDMOs Embrace Digital Manufacturing

CDMOs are increasingly resorting to data-driven techniques to make manufacturing more efficient.

“In time, all CDMOs are likely to go digital. Customer demand for high-quality products and information will cause data-driven manufacturing to become the norm.” - Lead Scientist, Tier 1 CDMO, USA

North America is the Largest Biologics CDMO Market

North America is the largest biologics CDMO market while APAC is expected to witness the highest CAGR in the next 5 years, hinged on China. To leverage growth opportunities in APAC, in April 2021, Lonza extended its partnership with Chinese firm Junshi Biosciences to advance and manufacture biologics at its site in Guangzhou, China.

Competitive Landscape Analysis: Biologics CDMO Market

The global biologics CDMO market is characterized by a high degree of fragmentation. Some of the leading companies in this market include Lonza, Catalent, Samsung Biologics, Fujifilm, Wuxi Biologics, and Boehringer Ingelheim. While some of the other promising players are Halix, Cobra Biologics, ABL, Biovian, SK Bioscience, IDT, AGC Biologics, Patheon, Abbvie, Novasep, and Emergent Biosolutions.

Get Customized Report on Biologics CDMO Market @ https://meditechinsights.com/global-biologics-cdmo-market/

Comments

Post a Comment

Popular posts from this blog

Global Weight Management Market Size, Share, Analysis, Growth, Forecasts, Trends, Developments & Scope by 2027

In an era, where health and wellness have become paramount, the weight management market has experienced a significant transformation. The Weight Management Market Research Report for 2023 unveils key insights into the latest trends, innovations, and challenges facing this dynamic sector. As individuals across the globe become more conscious of their health and weight, the market is evolving to meet their diverse needs. This report provides a comprehensive overview of the weight management industry, highlighting the factors driving its growth, emerging market segments, and the strategies employed by key players to stay ahead in this competitive landscape. Growing Obesity Rate Across the World: Weight Management Market The report begins by addressing the pressing issue of the global obesity epidemic. With a focus on the alarming statistics and the societal implications of this health crisis, it establishes the context in which the weight management market operates. The report delves in...
Read more

Global Genomics Market Report Reveals Rapid Growth & Transformative Trends in the Genomic Industry by 2027

In the ever-evolving landscape of healthcare, genomics is making headlines for its groundbreaking contributions to personalized medicine, disease understanding, and advancements in pharmaceutical research. The Global Genomics Market Report for 2023 highlights the impressive growth and transformative trends within the genomics industry, shedding light on the exciting potential of genomics in shaping the future of healthcare. I. The Genomics Market Landscape The report's comprehensive analysis of the global genomics market reveals a dynamic and rapidly expanding landscape. With a CAGR of over [X]% during the forecast period, the industry is experiencing unprecedented growth. Key factors driving this growth include increased adoption of genomics in clinical diagnostics, expanding genomics research initiatives, and the development of advanced sequencing technologies. II. Personalized Medicine Revolution One of the most exciting trends highlighted in the report is the integration of ge...
Read more

Global ATMPs Consulting Market Research Report 2027 - Competitive Analysis by Size, Share, Access, Growth, Demand & Industry Solutions

Advanced therapy medicinal products (ATMPs) are medicines for human utilization which are based on genes, tissues, or cells. They provide revolutionary and novel opportunities for the treatment of diseases and injuries. ATMPs primarily target diseases with unfulfilled medical demands. It has an extensive therapeutic potential for treating multiple types of diseases such as cancer, neurodegenerative diseases, and cardiovascular diseases. Development Complexities and Regulatory Adaptations Drives the ATMPs Consulting Market Growth The development of ATMPs is a complex manufacturing process resulting from handling living tissues or generating GMOs. The huge variety of ATMPs and their inherent complexity offers analytical development challenges. Specific characterization, potency, purity, and identity assays are needed for each product. Evolving regulatory needs for ATMPs in developed regions such as EU and U.S. and the need to meet demanding regulatory expectations pose various regulator...
Read more